Trials / Completed
CompletedNCT05535751
Cefepime vs. Carbapenems for Treating AmpC β-lactamase-producing Enterobacteriaceae Bloodstream Infections
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Recent international recommendations suggest the use of carbapenem rather than cefepime in this situation, but with a low level of evidence, given the few existing studies. As cefepime is a less broad-spectrum antibiotic than carbapenems, its use would limit the selection of multidrug-resistant bacteria.
Conditions
Timeline
- Start date
- 2022-07-20
- Primary completion
- 2023-05-20
- Completion
- 2023-06-20
- First posted
- 2022-09-10
- Last updated
- 2023-12-13
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05535751. Inclusion in this directory is not an endorsement.